Recursion Pharmaceuticals (RXRX)
(Real Time Quote from BATS)
$8.39 USD
+0.27 (3.33%)
Updated Apr 29, 2024 01:22 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Recursion Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -328.07 | -239.48 | -186.48 | -87.01 | -61.88 |
Depreciation/Amortization & Depletion | 24.40 | 11.76 | 8.41 | 3.94 | 3.04 |
Net Change from Assets/Liabilities | -50.26 | 105.75 | -0.31 | 30.83 | 0.41 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 66.14 | 38.45 | 19.77 | 6.83 | 1.39 |
Net Cash From Operating Activities | -287.78 | -83.52 | -158.61 | -45.40 | -57.04 |
Property & Equipment | -11.96 | -37.06 | -39.80 | -5.83 | -3.91 |
Acquisition/ Disposition of Subsidiaries | 1.84 | 0.00 | 0.00 | -2.60 | 0.00 |
Investments | 0.48 | 230.61 | -231.95 | 0.60 | 0.00 |
Other Investing Activities | -0.60 | -0.30 | 0.00 | -0.90 | 0.00 |
Net Cash from Investing Activities | -10.23 | 193.25 | -271.74 | -8.74 | -3.91 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 128.09 | 143.71 | 462.90 | 239.81 | 119.98 |
Issuance (Repayment) of Debt | -0.77 | -0.09 | -12.80 | 6.32 | 0.71 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 12.81 | 10.72 | 8.44 | 0.00 | -0.28 |
Net Cash from Financing Activities | 140.13 | 154.35 | 458.54 | 246.14 | 120.41 |
Effect of Exchange Rate Changes | 0.19 | -0.31 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -157.69 | 263.76 | 28.18 | 192.00 | 59.46 |
Cash at Beginning of Period | 559.11 | 295.35 | 267.17 | 75.17 | 15.71 |
Cash at End of Period | 401.43 | 559.11 | 295.35 | 267.17 | 75.17 |
Diluted Net EPS | -1.58 | -1.36 | -1.49 | -3.99 | NA |
Fiscal Year End for Recursion Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -328.07 | -235.07 | -142.05 | -65.33 |
Depreciation/Amortization & Depletion | NA | 24.40 | 16.85 | 9.27 | 3.73 |
Net Change from Assets/Liabilities | NA | -50.26 | -38.99 | -34.53 | -24.40 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 66.14 | 43.51 | 26.52 | 12.69 |
Net Cash From Operating Activities | NA | -287.78 | -213.70 | -140.78 | -73.32 |
Property & Equipment | NA | -11.96 | -9.89 | -9.14 | -5.18 |
Acquisition/ Disposition of Subsidiaries | NA | 1.84 | 1.92 | 1.92 | 0.00 |
Investments | NA | 0.48 | 0.48 | 0.00 | 0.00 |
Other Investing Activities | NA | -0.60 | -0.25 | -0.17 | -0.17 |
Net Cash from Investing Activities | NA | -10.23 | -7.74 | -7.39 | -5.34 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 128.09 | 50.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | -0.77 | -0.07 | -0.05 | -0.02 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 12.81 | 9.55 | 5.76 | 1.95 |
Net Cash from Financing Activities | NA | 140.13 | 59.47 | 5.71 | 1.92 |
Effect of Exchange Rate Changes | NA | 0.19 | 0.06 | 0.18 | 0.00 |
Net Change In Cash & Equivalents | NA | -157.69 | -161.91 | -142.29 | -76.74 |
Cash at Beginning of Period | NA | 559.11 | 559.11 | 559.11 | 559.11 |
Cash at End of Period | NA | 401.43 | 397.21 | 416.82 | 482.38 |
Diluted Net EPS | NA | -0.43 | -0.43 | -0.38 | -0.34 |